Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes

Inclusion Criteria: * Age ≥ 18 years * T1D ≥ 2 years * Use of insulin pump therapy (without sensor-augmented insulin suspension/adjustment functionality) ≥ 6 months * Use of CGM (real-time or intermittently scanned) ≥ 3 months and ≥ 70% during the previous 14 days * HbA1c ≤ 70 mmol/l (8.5%) * Performs aerobic exercise on a regular basis (≥ 2 times per week; self-reported) and desires to exercise per American Diabetes Association guidelines (150 minutes per week) during the study. * Use of carbohydrate counting and bolus calculator (self-reported) * Sensor glucose level \< 3.9 mmol/l on ≥ 4/14 previous days assessed by CGM data Exclusion Criteria: * Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period and within 30 days prior to study start * Known or suspected allergies to glucagon or related products * History of hypersensitivity or allergic reaction to dasiglucagon or any of the excipients * Patients with pheochromocytoma or insulinoma * Hypoglycemia unawareness * Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods * Inability to understand the individual information and to give informed consent * Current participation in another clinical trial that, in the judgment of the investigator, will compromise the results of the study or the safety of the subject * Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation